On March 5, Integra LifeSciences
- Though sales were up more than 18%, acquisitions played a definite (though undisclosed) role.
- Integra LifeSciences management continues to look for long-term reported revenue growth of 20%-30%, and organic revenue growth in excess of 15%.
(Figures in thousands, except per-share data)
Income Statement Highlights
Avg. Est. |
Q4 2005 |
Q4 2004 |
% Change |
|
---|---|---|---|---|
Sales |
$73,160 |
$72,985 |
$61,811 |
18.1 |
Net Profit |
-- |
$12,659 |
$10,437 |
21.3 |
EPS |
$0.37 |
$0.37 |
$0.30 |
23.3 |
Get back to basics with a look at the income statement.
Margin Checkup
Q4 2005 |
Q4 2004 |
% Change |
|
---|---|---|---|
Gross Margin |
63.07% |
62.43% |
0.63 |
Op. Margin |
23.38% |
22.05% |
1.32 |
Net Margin |
17.34% |
16.89% |
0.46 |
Likewise with net profit and EPS, the gross, operating, and net margins reflect the exclusion of certain costs related to facility closures and employee terminations. As reported, the margins were 61.3%, 20.4%, and 15.4%.
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
Assets |
Q4 2005 |
Q4 2004 |
% Change |
---|---|---|---|
Cash+ ST Invest. |
$143,384 |
$195,982 |
(26.8) |
Inventory |
$67,476 |
$55,947 |
20.6 |
Accounts Rec. |
$49,007 |
$46,765 |
4.8 |
Liabilities |
Q4 2005 |
Q4 2004 |
% Change |
---|---|---|---|
Long-Term Debt |
$118,378 |
$118,900 |
(0.4) |
Accounts Pay. |
na |
na |
na |
Cash Flow Highlights
Although the company did not provide a cash flow statement, management did announce that operating cash flow was $15.1 million for the quarter and $57 million for the full year. That compares to $39 million last year.
Find out why Fools always follow the money.
Related Companies:
-
Medtronic
(NYSE:MDT) -
Smith & Nephew
(NYSE:SNN) -
Wright Medical
(NASDAQ:WMGI) -
Johnson & Johnson
(NYSE:JNJ) -
Cardinal Health
(NYSE:CAH)
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
Fool contributor Stephen Simpson owns shares of Johnson & Johnson, but he has no financial interest in any of the other stocks mentioned.